Plasma proteins: Unique biopharmaceuticals - unique economics

Pharmaceuticals Policy and Law

Volumn 7, Issue , 2005, Pages 209-218

  Burnouf, Thierry ^a  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013616634     PISSN: 13892827     EISSN: 2210495X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. T. Burnouf, C. Kappelsberger, K. Frank and T. Burkhardt, Protein composition and activation markers in plasma collected by three apheresis procedures, Transfusion 43 (2003), 1223-1230.
2. S. Runkel, H. Haubelt, W. Hitzler and P. Hellstern, The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood, Transfusion 45 (2005), 427-432.
3. T. Burnouf, Integration of chromatography with traditional plasma protein fractionation methods, Bioseparation 1 (1991), 383-396.
4. E. Cohn, L. Strong, W. Hughes, D. Mulford, J. Ashworth, M. Melin and H. Taylor, Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids, J Am Chem Soc 68 (1946), 459-475.
5. T. Burnouf, New approaches to product isolation, in: Plasma and Recombinant Blood Products in Medical Therapy, C. Prowse, ed., John Wiley & Sons Ltd, 1992, pp. 67-87.
6. J.A. Levy, G.A. Mitra, M.F. Wong and M.M. Mozen, Inactivation by wet and dry heat of AIDSassociated retroviruses during factor VIII purification from plasma, Lancet 1 (1985), 1456-1457.
7. M.S. Horowitz, C. Rooks, B. Horowitz and M.W. Hilgartner, Virus safety of solvent/detergenttreated antihaemophilic factor concentrate, Lancet 2 (1988), 186-189.
8. T. Nowak, M. Niedrig, D. Bernhardt and J. Hilfenhaus, Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation, Dev Biol Stand 81 (1993), 169-176.
9. T. Burnouf and M. Radosevich, Nanofiltration of plasma-derived biopharmaceutical products, Haemophilia 9 (2003), 24-37.
10. WHO, Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. www.WHO.int, Geneva, 2003.
11. M.E. Chamberland, H.J. Alter, M.P. Busch, G. Nemo and M. Ricketts, Emerging infectious disease issues in blood safety, Emerg Infect Dis 7 (2001), 552-553.
12. A. Farrugia, Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives, Haemophilia 8 (2002), 230-235.
13. D. Bonn, Blood transfusion linked to vCJD death, Lancet Infect Dis 4 (2004), 65.
14. T.R. Kreil, A. Berting, O. Kistner and J. Kindermann, West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data, Transfusion 43 (2003), 1023-1028.
15. T. Burnouf and M. Radosevich, Reducing the risk of infection from plasma products: specific preventative strategies, Blood Rev 14 (2000), 94-110.
16. CPMP, EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/ Pharmacy and Working Party on Safety Medicines. http://www.emea.eu.int, Biologicals 19 (1991), 247-251.
17. CPMP, Note for guidance on plasma -derived medicinal products. CPMP/BWP/269/95 rev.3. http://www.emea.eu.int: The European Agency for the Evaluation of Medicinal Products, 2001.
18. CHMP, Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regards to VCJD risk. PMP/BWP/CPMP/5136/03. http://www.emea.eu.int, London, European Medicines Agency, 2004.